BLUE vs. SGMO, DBVT, BCAB, LIFE, MOLN, OMGA, SCLX, OTLK, VIGL, and CRIS
Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), BioAtla (BCAB), aTyr Pharma (LIFE), Molecular Partners (MOLN), Omega Therapeutics (OMGA), Scilex (SCLX), Outlook Therapeutics (OTLK), Vigil Neuroscience (VIGL), and Curis (CRIS). These companies are all part of the "biological products, except diagnostic" industry.
bluebird bio (NASDAQ:BLUE) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
bluebird bio received 596 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
bluebird bio has a net margin of -419.64% compared to Sangamo Therapeutics' net margin of -1,749.06%. bluebird bio's return on equity of -34.32% beat Sangamo Therapeutics' return on equity.
bluebird bio has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.
bluebird bio presently has a consensus price target of $5.74, indicating a potential upside of 457.71%. Sangamo Therapeutics has a consensus price target of $5.67, indicating a potential upside of 772.33%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than bluebird bio.
87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 2.1% of bluebird bio shares are owned by company insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Sangamo Therapeutics had 4 more articles in the media than bluebird bio. MarketBeat recorded 14 mentions for Sangamo Therapeutics and 10 mentions for bluebird bio. Sangamo Therapeutics' average media sentiment score of 0.33 beat bluebird bio's score of 0.00 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.
Summary
bluebird bio and Sangamo Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get bluebird bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bluebird bio Competitors List
Related Companies and Tools
